DOI QR코드

DOI QR Code

Prognostic Significance of CYFRA21-1, CEA and Hemoglobin in Patients with Esophageal Squamous Cancer Undergoing Concurrent Chemoradiotherapy

  • Zhang, Hai-Qin (Department of Radiation Oncology, Shandong Cancer Hospital) ;
  • Wang, Ren-Ben (Department of Radiation Oncology, Shandong Cancer Hospital) ;
  • Yan, Hong-Jiang (Department of Radiation Oncology, Shandong Cancer Hospital) ;
  • Zhao, Wei (Department of Radiation Oncology, Shandong Cancer Hospital) ;
  • Zhu, Kun-Li (Department of Radiation Oncology, Shandong Cancer Hospital) ;
  • Jiang, Shu-Mei (Department of Radiation Oncology, Shandong Cancer Hospital) ;
  • Hu, Xi-Gang (Department of Radiation Oncology, Shandong Cancer Hospital) ;
  • Yu, Jin-Ming (Department of Radiation Oncology, Shandong Cancer Hospital)
  • 발행 : 2012.01.31

초록

Purpose: To evaluate the prognostic value of serum CYFRA21-1, CEA and hemoglobin levels regarding long-term survival of patients with esophageal squamous cell carcinoma (ESCC) treated with concurrent chemoradiotherapy (CRT). Methods: Age, gender, Karnofsky Performance Status (KPS), tumor location, tumor length, T stage, N stage and serum hemoglobin, and CYFRA21-1 and CEA levels before concurrent CRT were retrospectively investigated and related to outcome in 113 patients receiving 5-fluorouracil and cisplatin combined with radiotherapy for ESCC. The Kaplan-Meier method was used to analyze prognosis, the log-rank to compare groups, the Cox proportional hazards model for multivariate analysis, and ROC curve analysis for assessment of predictive performance of biologic markers. Results: The median survival time was 20.1 months and the 1-, 2-, 3-, 5- year overall survival rates were 66.4%, 43.4%, 31.9% and 15.0%, respectively. Univariate analysis showed that factors associated with prognosis were KPS, tumor length, T-stage, N-stage, hemoglobin, CYFRA21-1 and CEA level. Multivariate analysis showed T-stage, N-stage, hemoglobin, CYFRA21-1 and CEA level were independent predictors of prognosis. By ROC curve, CYFRA21-1 and hemoglobin showed better predictive performance for OS than CEA (AUC= 0.791, 0.704, 0.545; P=0.000, 0.000, 0.409). Conclusions: Of all clinicopathological and molecular factors, T stage, N stage, hemoglobin, CYFRA21-1 and CEA level were independent predictors of prognosis for patients with ESCC treated with concurrent CRT. Among biomarkers, CYFRA21-1 and hemoglobin may have a better predictive potential than CEA for long-term outcomes.

키워드

참고문헌

  1. Bedenne L, Michel P, Bouche O, et al (2007). Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol, 25,1160-8. https://doi.org/10.1200/JCO.2005.04.7118
  2. Brockmann JG, St Nottberg H, Glodny B, et al (2000). CYFRA 21-1 serum analysis in patients with esophageal cancer. Clin Cancer Res, 6, 4249-52.
  3. Hamada Y, Yamamura M, Hioki K, et al (1985). Immunohistochemical study of carcinoembryonic antigen in patients with colorectal cancer. Cancer, 55, 136-41. https://doi.org/10.1002/1097-0142(19850101)55:1<136::AID-CNCR2820550121>3.0.CO;2-P
  4. Hu Y, Zheng B, Rong TH, Fu JH, et al (2010). Prognostic analysis of the patients with stageIII esophageal squamous cell carcinoma after radical esophagectomy. Chin J Cancer, 29, 178-83. https://doi.org/10.5732/cjc.009.10314
  5. Kawashima M, Ikeda H, Yorozu A, et al (1998). Clinical features of esophageal cancer in the octogenarian treated by definitive radiotherapy: a multi-institutional retrospective survey. Jpn J Clin Oncol, 28, 301-7. https://doi.org/10.1093/jjco/28.5.301
  6. Kijima H, Oshiba G, Kenmochi T, et al (2000). Stomal CEA immunoreactivity is correlated with lymphatic invasion of human esophageal carcinoma. Int J Oncol, 16, 677-82.
  7. Kunisaki C, Akiyama H, Nomura M, et al (2005). Developing an appropriate staging system for esophageal carcinoma. J Am Coll Surg, 201, 884-90. https://doi.org/10.1016/j.jamcollsurg.2005.07.002
  8. Medical Research Council Oesophageal Cancer Working Party. (2002). Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet, 359, 1727-33. https://doi.org/10.1016/S0140-6736(02)08651-8
  9. Midiri G, Amanti C, Benedetti M, et al (1985). CEA tissue staining in colorectal cancer patients. A way to improve the usefulness of serial serum CEA evaluation. Cancer, 55, 2624-9. https://doi.org/10.1002/1097-0142(19850601)55:11<2624::AID-CNCR2820551115>3.0.CO;2-#
  10. Nakamura T, Ide H, Eguchi R, et al (1998). CYFRA 21-1 as a tumor marker for squamous cell carcinoma of the esophagus. Dis Esophagus, 11, 35-9. https://doi.org/10.1093/dote/11.1.35
  11. Park JW, Kim JH, Choi EK, et al (2011). Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys, 81, 691-7. https://doi.org/10.1016/j.ijrobp.2010.06.041
  12. Rades D, Lang S, Schild SE, et al (2006). Prognostic value of haemoglobin levels during concurrent radio-chemotherapy in the treatment of oesophageal cancer. Clin Oncol, 18, 139-44. https://doi.org/10.1016/j.clon.2005.10.007
  13. Rades D, Schild SE, Bahrehmand R, et al (2005). Prognostic factors in the nonsurgical treatment of esophageal carcinoma with radiotherapy or radiochemotherapy: the importance of pretreatment hemoglobin levels. Cancer, 103, 1740-6. https://doi.org/10.1002/cncr.20952
  14. Rice TW, Zuccaro G Jr, Adelstein DJ, et al (1998). Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status. Ann Thorac Surg, 65, 787-92. https://doi.org/10.1016/S0003-4975(97)01387-8
  15. Shimada H, Nabeya Y, Okazumi S, et al (2003). Prognostic significance of CYFRA 21-1 in patients with esophageal squamous cell carcinoma. J Am Coll Surg, 196, 573-8. https://doi.org/10.1016/S1072-7515(02)01905-1
  16. Tachibana M, Kinugasa S, Yoshimura H, et al (2005). Clinical outcomes of extended esophagectomy with three-field lymph node dissection for esophageal squamous cell carcinoma. Am J Surg, 189, 98-109. https://doi.org/10.1016/j.amjsurg.2004.10.001
  17. Tepper J, Krasna MJ, Niedzwiecki D, et al (2008). Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol, 26, 1086-92. https://doi.org/10.1200/JCO.2007.12.9593
  18. Urba SG, Orringer MB, Turrisi A, et al (2001). Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol, 19, 305-13. https://doi.org/10.1200/JCO.2001.19.2.305
  19. Wiggers T, Arends JW, Verstijnen C, et al (1986). Prognostic significance of CEA immunoreactivity patterns in large bowel carcinoma tissue. Br J Cancer, 54, 409-14. https://doi.org/10.1038/bjc.1986.191
  20. Yamamoto K, Oka M, Hayashi H, et al (1997). CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma. Cancer, 79, 1647-55. https://doi.org/10.1002/(SICI)1097-0142(19970501)79:9<1647::AID-CNCR3>3.0.CO;2-9
  21. Yi Y, Li B, Wang Z, Sun H, et al (2009). CYFRA21-1 and CEA are useful markers for predicting the sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma. Biomarkers, 14, 480-5. https://doi.org/10.3109/13547500903180265

피인용 문헌

  1. Cytokines and tumor markers in potentially malignant disorders and oral squamous cell carcinoma: a pilot study vol.20, pp.5, 2013, https://doi.org/10.1111/odi.12160
  2. Lower mean corpuscular hemoglobin concentration is associated with unfavorable prognosis of resected lung cancer vol.10, pp.14, 2014, https://doi.org/10.2217/fon.14.121
  3. Preliminary Evaluation of Clinical Utility of CYFRA 21-1, CA 72-4, NSE, CA19-9 and CEA in Stomach Cancer vol.15, pp.12, 2014, https://doi.org/10.7314/APJCP.2014.15.12.4933
  4. HOXB7 Predicts Poor Clinical Outcome in Patients with Advanced Esophageal Squamous Cell Cancer vol.15, pp.4, 2014, https://doi.org/10.7314/APJCP.2014.15.4.1563
  5. Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303) vol.22, pp.6, 2017, https://doi.org/10.1007/s10147-017-1154-6